News
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...
Global Fund aims for the first shipment to reach at least one African country by year-end. Read more at straitstimes.com.
1h
Louisville Public Media on MSNHIV community faces a double whammy: Medicaid reductions and CDC funding cutsC ongress just passed a sweeping bill that includes changes to Medicaid expected to cut millions of people with low incomes ...
Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...
A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...
The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...
The results expose a striking prevalence of high-risk sexual behaviours. Over one-third of participants (34.0%) disclosed ...
People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...
State's Health Outreach and Prevention program will end June 30 after federal funding cuts to HIV outreach and prevention ...
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalised plans to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results